Forty51 Ventures
Overview
Forty51 Ventures is a biotech venture capital firm that focuses on company formation and early-stage investments in European biotech opportunities with a clear path to the clinic.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Allegria Therapeutics AG | Dec 2025 | Seed | Co-investor |
| Mysthera Therapeutics AG | Aug 2023 | Seed | Lead |
| Ferrosa Therapeutics | Apr 2026 | Seed | Lead |
| Mosanna Therapeutics | Jun 2025 | Series A | Co-investor |
| Melodia Therapeutics AG | Jun 2024 | Seed | Lead |
Key People
Sara Núñez-Garcia
Co-Founding Partner
Alan S. Roemer
Strategic Partner
Tamas Schweighoffer
Partner
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Forty51 Ventures based?
Forty51 Ventures is headquartered in Basel, Switzerland.
When was Forty51 Ventures founded?
Forty51 Ventures was founded in 2022.
How many portfolio companies does Forty51 Ventures have?
Forty51 Ventures has 5 portfolio companies in Caplight's dataset.
What are some companies in Forty51 Ventures's portfolio?
Portfolio companies visible on Caplight include Allegria Therapeutics AG, Mysthera Therapeutics AG, Ferrosa Therapeutics, Mosanna Therapeutics, Melodia Therapeutics AG.
What was Forty51 Ventures's most recent investment shown here?
Forty51 Ventures's most recent investment in this portfolio sample was in Ferrosa Therapeutics in 2026.
What sectors does Forty51 Ventures focus on?
Forty51 Ventures focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Forty51 Ventures focus on?
Forty51 Ventures typically invests at the Early stage.
What is Forty51 Ventures's AUM?
Forty51 Ventures's assets under management are estimated at over $43.0M.